Summary
NOVA Chart
Novo Nordisk: This Won't Last
Novo Nordisk is still the GLP-1 king, with over 65% market share and blockbuster drugs like Ozempic and Wegovy continuing to drive global growth. The recent stock correction presents a rare long-term buying opportunity, supported by a strong pipeline, manufacturing expansion, and international momentum. The valuation is attractive relative to historical metrics, with a +3% yield and significant room for capital appreciation as demand continues to outpace supply.
The rise, fall and rise again of Novo Nordisk shares
CNBC's Silvia Amaro takes a look at the rise and fall in Novo Nordisk shares.
Novo Nordisk: More Pain On The Horizon
Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook, signaling challenges ahead. Competition from Eli Lilly is intensifying, forcing Novo to increase marketing spend, which risks margin compression and weaker shareholder returns. Despite a significant share price drop, Novo Nordisk remains overvalued with a forward P/FCF ratio of 35, far above sector medians.
Novo Nordisk A/S Sponsored ADR Dividends
 NOVA 4 months ago | Other | €0.98 Per Share |
| NOVA 11 months ago | Other | €0.44 Per Share |
| NOVA 22 Mar 2024 | Other | €0.79 Per Share |
| NOVA 18 Aug 2023 | Other | €0.37 Per Share |
| NOVA 24 Mar 2023 | Other | €0.5 Per Share |
Novo Nordisk A/S Sponsored ADR Earnings
| 5 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 5 Nov 2025 (In 2 months) Date | | 5.86 Cons. EPS | - EPS |
| 6 Aug 2025 Date | | 6.01 Cons. EPS | - EPS |
| 7 May 2025 Date | | - Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| NOVA 4 months ago | Other | €0.98 Per Share |
| NOVA 11 months ago | Other | €0.44 Per Share |
| NOVA 22 Mar 2024 | Other | €0.79 Per Share |
| NOVA 18 Aug 2023 | Other | €0.37 Per Share |
| NOVA 24 Mar 2023 | Other | €0.5 Per Share |
| 5 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 5 Nov 2025 (In 2 months) Date | | 5.86 Cons. EPS | - EPS |
| 6 Aug 2025 Date | | 6.01 Cons. EPS | - EPS |
| 7 May 2025 Date | | - Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
Novo Nordisk A/S Sponsored ADR (NOVA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Novo Nordisk A/S Sponsored ADR ever had a stock split?
Novo Nordisk A/S Sponsored ADR Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Lars Fruergaard Jorgensen CEO | XMUN Exchange | US6701002056 ISIN |
| DK Country | 77,406 Employees | 18 Aug 2025 Last Dividend | 20 Sep 2023 Last Split | - IPO Date |
Overview
Novo Nordisk A/S is an established global pharmaceutical company with a heritage dating back to 1923. With its headquarters in Bagsvaerd, Denmark, the company has a widespread operational reach across Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and other international markets. Novo Nordisk is committed to discovering and developing innovative pharmaceutical products, focusing primarily on Diabetes and Obesity Care, and Rare Disease. The company has carved a niche for itself by not just being a manufacturer but also engaging in the research and development of new pharmaceutical products, ensuring they provide contemporary and efficient solutions to the healthcare challenges of today.
Products and Services
Novo Nordisk A/S offers a comprehensive range of healthcare products and solutions aimed at addressing some of the most challenging diseases. With a focus on quality and innovation, their offerings encompass:
- Diabetes and Obesity Care: This segment includes products specifically designed to manage diabetes and obesity, along with related cardiovascular conditions and other emerging therapeutic areas. The company’s commitment to combating diabetes and obesity is reflected in its continuous pursuit of safer and more effective treatments.
- Rare Disease: Novo Nordisk takes a targeted approach to rare diseases, focusing on rare blood disorders, rare endocrine disorders, and providing hormone replacement therapy. These specialized treatments are developed with the aim of addressing medical needs that are often underserved, demonstrating the company's dedication to all patients, regardless of the rarity of their condition.
- Insulin Pens: The company produces a variety of insulin pens that are designed for ease of use, ensuring that patients can manage their condition with confidence and precision. These devices are a testament to Novo Nordisk’s focus on patient-centric innovations.
- Growth Hormone Pens: These pens are part of the portfolio intended for patients requiring growth hormone therapy. They simplify the administration process, making treatment more accessible and manageable for patients.
- Injection Needles: To complement their insulin and growth hormone pens, Novo Nordisk also supplies high-quality injection needles, designed for minimal discomfort and optimal medication delivery.
- Smart Solutions for Diabetes: Innovating beyond conventional treatments, Novo Nordisk offers smart insulin pens and Dose Check, an insulin dose guidance application. These smart solutions enhance the treatment experience by integrating advanced technology with patient care, facilitating better management of diabetes.
Through a collaboration agreement with Aspen Pharmaceuticals, Novo Nordisk also ensures the production of insulin products, highlighting their commitment to making essential medications accessible. The company's enduring legacy and forward-looking approach have positioned it as a key player in the global pharmaceutical industry, dedicated to improving the lives of patients worldwide.
Contact Information
